Julie Støy1, Jørgen Olsen2, Soo-Young Park3,4, Søren Gregersen5, Claudia U Hjørringgaard6, Graeme I Bell3,4. 1. Department of Internal Medicine and Endocrinology, Aarhus University Hospital, Nørrebrogade 44, 8000, Aarhus C, Denmark. julistoe@rm.dk. 2. ADME Department, Novo Nordisk, Måløv, Denmark. 3. Department of Medicine, University of Chicago, Chicago, IL, USA. 4. Department of Human Genetics, University of Chicago, Chicago, IL, USA. 5. Department of Internal Medicine and Endocrinology, Aarhus University Hospital, Aarhus, Denmark. 6. Protein & Peptide Chemistry, Novo Nordisk, Måløv, Denmark.
Abstract
AIMS/HYPOTHESIS: Heterozygous mutations in the insulin gene that affect proinsulin biosynthesis and folding are associated with a spectrum of diabetes phenotypes, from permanent neonatal diabetes to MODY. In vivo studies of these mutations may lead to a better understanding of insulin mutation-associated diabetes and point to the best treatment strategy. We studied an 18-year-old woman with MODY heterozygous for the insulin mutation p.R46Q (GlnB22-insulin), measuring the secretion of mutant and wild-type insulin by LC-MS. The clinical study was combined with in vitro studies of the synthesis and secretion of p.R46Q-insulin in rat INS-1 insulinoma cells. METHODS: We performed a standard 75 g OGTT in the 18-year-old woman and measured plasma glucose and serum insulin (wild-type insulin and GlnB22-insulin), C-peptide, proinsulin, glucagon and amylin. The affinity of GlnB22-insulin was tested on human insulin receptors expressed in baby hamster kidney (BHK) cells. We also examined the subcellular localisation, secretion and impact on cellular stress markers of p.R46Q-insulin in INS-1 cells. RESULTS: Plasma GlnB22-insulin concentrations were 1.5 times higher than wild-type insulin at all time points during the OGTT. The insulin-receptor affinity of GlnB22-insulin was 57% of that of wild-type insulin. Expression of p.R46Q-insulin in INS-1 cells was associated with decreased insulin secretion, but not induction of endoplasmic reticulum stress. CONCLUSIONS/ INTERPRETATION: The results show that beta cells can process and secrete GlnB22-insulin both in vivo and in vitro. Our combined approach of immunoprecipitation and LC-MS to measure mutant and wild-type insulin may be useful for the study of other mutant insulin proteins. The ability to process and secrete a mutant protein may predict a more benign course of insulin mutation-related diabetes. Diabetes develops when the beta cell is stressed because of increased demand for insulin, as observed in individuals with other insulin mutations that affect the processing of proinsulin to insulin or mutations that reduce the affinity for the insulin receptor.
AIMS/HYPOTHESIS: Heterozygous mutations in the insulin gene that affect proinsulin biosynthesis and folding are associated with a spectrum of diabetes phenotypes, from permanent neonatal diabetes to MODY. In vivo studies of these mutations may lead to a better understanding of insulin mutation-associated diabetes and point to the best treatment strategy. We studied an 18-year-old woman with MODY heterozygous for the insulin mutation p.R46Q (GlnB22-insulin), measuring the secretion of mutant and wild-type insulin by LC-MS. The clinical study was combined with in vitro studies of the synthesis and secretion of p.R46Q-insulin in rat INS-1 insulinoma cells. METHODS: We performed a standard 75 g OGTT in the 18-year-old woman and measured plasma glucose and serum insulin (wild-type insulin and GlnB22-insulin), C-peptide, proinsulin, glucagon and amylin. The affinity of GlnB22-insulin was tested on human insulin receptors expressed in baby hamster kidney (BHK) cells. We also examined the subcellular localisation, secretion and impact on cellular stress markers of p.R46Q-insulin in INS-1 cells. RESULTS: Plasma GlnB22-insulin concentrations were 1.5 times higher than wild-type insulin at all time points during the OGTT. The insulin-receptor affinity of GlnB22-insulin was 57% of that of wild-type insulin. Expression of p.R46Q-insulin in INS-1 cells was associated with decreased insulin secretion, but not induction of endoplasmic reticulum stress. CONCLUSIONS/ INTERPRETATION: The results show that beta cells can process and secrete GlnB22-insulin both in vivo and in vitro. Our combined approach of immunoprecipitation and LC-MS to measure mutant and wild-type insulin may be useful for the study of other mutant insulin proteins. The ability to process and secrete a mutant protein may predict a more benign course of insulin mutation-related diabetes. Diabetes develops when the beta cell is stressed because of increased demand for insulin, as observed in individuals with other insulin mutations that affect the processing of proinsulin to insulin or mutations that reduce the affinity for the insulin receptor.
Entities:
Keywords:
Insulin gene; Maturity-onset diabetes of the young; Mutant insulin
Authors: Ming Liu; Israel Hodish; Leena Haataja; Roberto Lara-Lemus; Gautam Rajpal; Jordan Wright; Peter Arvan Journal: Trends Endocrinol Metab Date: 2010-08-18 Impact factor: 12.015
Authors: Lenka Dusatkova; Petra Dusatkova; Jan Vosahlo; Klara Vesela; Ondrej Cinek; Jan Lebl; Stepanka Pruhova Journal: Eur J Med Genet Date: 2015-02-23 Impact factor: 2.708
Authors: John G Menting; Yanwu Yang; Shu Jin Chan; Nelson B Phillips; Brian J Smith; Jonathan Whittaker; Nalinda P Wickramasinghe; Linda J Whittaker; Vijay Pandyarajan; Zhu-li Wan; Satya P Yadav; Julie M Carroll; Natalie Strokes; Charles T Roberts; Faramarz Ismail-Beigi; Wieslawa Milewski; Donald F Steiner; Virander S Chauhan; Colin W Ward; Michael A Weiss; Michael C Lawrence Journal: Proc Natl Acad Sci U S A Date: 2014-08-04 Impact factor: 11.205
Authors: Sindhu Rajan; Stefani C Eames; Soo-Young Park; Christine Labno; Graeme I Bell; Victoria E Prince; Louis H Philipson Journal: Am J Physiol Endocrinol Metab Date: 2009-12-01 Impact factor: 4.310
Authors: Anoop Arunagiri; Leena Haataja; Corey N Cunningham; Neha Shrestha; Billy Tsai; Ling Qi; Ming Liu; Peter Arvan Journal: Ann N Y Acad Sci Date: 2018-01-28 Impact factor: 5.691
Authors: Nischay K Rege; Ming Liu; Yanwu Yang; Balamurugan Dhayalan; Nalinda P Wickramasinghe; Yen-Shan Chen; Leili Rahimi; Huan Guo; Leena Haataja; Jinhong Sun; Faramarz Ismail-Beigi; Nelson B Phillips; Peter Arvan; Michael A Weiss Journal: Proc Natl Acad Sci U S A Date: 2020-11-05 Impact factor: 11.205
Authors: Matthew C Riddle; Louis H Philipson; Stephen S Rich; Annelie Carlsson; Paul W Franks; Siri Atma W Greeley; John J Nolan; Ewan R Pearson; Philip S Zeitler; Andrew T Hattersley Journal: Diabetes Care Date: 2020-12 Impact factor: 19.112